Mintu P. Turakhia et al. JACEP 2016;2:

Slides:

Advertisements

Similar presentations

Tom F. Brouwer et al. JACEP 2016;2:89-96

Advertisements

Prakash Harikrishnan et al. JACEP 2015;1:

Prakash Harikrishnan et al. JACEP 2015;1:

Noriko Kikuchi et al. JACEP 2016;2:

Baseline characteristics of patients

Waddah Maskoun et al. JACEP 2016;2:

Konstantinos C. Siontis et al. JACEP 2016;2:

Chin-Yu Lin et al. JACEP 2016;2:

Shadi Al Halabi et al. JACEP 2015;1:

Kenshi Hayashi et al. JACEP 2016;2:

Tom F. Brouwer et al. JACEP 2016;2:89-96

Ashish Shukla et al. JACEP 2015;1:41-51

Dileep Raman et al. JACEP 2017;3:

Thomas C. Crawford et al. JACEP 2017;3:

Thomas C. Crawford et al. JACEP 2017;j.jacep

Belinda Gray et al. JCHF 2013;1:

David F. Katz et al. JACEP 2016;j.jacep

Simon W. Rabkin et al. JACEP 2017;j.jacep

Mintu P. Turakhia et al. JACEP 2016;2:

Wesley T. O’Neal et al. JACEP 2016;2:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Junjie Zhang et al. JACEP 2017;3:

Imran Niazi et al. JACEP 2017;j.jacep

Wayne L. Miller et al. JCHF 2013;1:

Giuseppe Boriani et al. JACEP 2016;2:

Mohit K. Turagam et al. JACEP 2017;3:

John A. Bittl et al. JACC 2016;68:

Prakash Harikrishnan et al. JACEP 2015;1:

Konstantinos C. Siontis et al. JACEP 2016;2:

K.R. Julian Chun et al. JACEP 2017;3:

Svend A. Mortensen et al. JCHF 2014;2:

S.M. Afzal Sohaib et al. JACEP 2015;1:

Prabhat Kumar et al. JACEP 2016;j.jacep

Yoshitaka Kimura et al. JACEP 2016;2:

Marwan Badri et al. JACEP 2015;1:

Vittorio Calzolari et al. JACEP 2017;3:

Patient characteristics: American vs Canadian transplant patients

Kenshi Hayashi et al. JACEP 2016;2:

David F. Katz et al. JACEP 2017;3:20-28

Neal A. Chatterjee et al. JCHF 2014;2:

P. Michael Grossman et al. JCIN 2009;2:

Moussa Mansour et al. JACEP 2016;j.jacep

Mintu P. Turakhia et al. JACEP 2016;2:

Simon W. Rabkin et al. JACEP 2017;3:

S.M. Afzal Sohaib et al. JACEP 2015;1:

Pugazhendhi Vijayaraman et al. JACEP 2015;1:

Noboru Ichihara et al. JACEP 2016;2:

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

Figure 2. Odds ratios (ORs) from the multivariate logistic regression analysis and hazard ratios (HRs) from the Cox regression analysis Odds ratios (ORs)

Stavros V. Konstantinides et al. JACC 2017;69:

Davide Capodanno et al. JCIN 2009;2:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Saadia Sherazi et al. JACEP 2015;1:74-80

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Christian Madelaire et al. JCHF 2018;6:

Jeffrey Senfield et al. JACEP 2017;3:

Increase of physical activity over time associated with lower HF risk

Maxime Berthelot-Richer et al. JIMG 2016;9:

Anneline S.J.M. te Riele et al. JACEP 2015;1:

Orly Vardeny et al. JCHF 2016;4:

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Francisco Alcocer, MD, Marjan Mujib, MD, Bruce Lowman, MD, Mark A

The ROC curves analyzing the sensitivity and specificity of rCBVmax values in astrocytomas for 1-year survival (A) and recurrence (B) show the optimal.

A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.

Daniele Muser et al. JACEP 2017;j.jacep

Volume 16, Issue 6, Pages (June 2019)

Cumulative probability of CIN2 stratified by HPV test results.

Presentation transcript:

Mintu P. Turakhia et al. JACEP 2016;2:426-433 Survival From All-Cause Mortality Kaplan Meier survival (lines) from all-cause mortality is shown with 95% confidence interval (CI) (shaded area). Use of the quadripolar system was associated with a lower risk of death compared to the bipolar system. The quadripolar group was more heavily censored because these patients were implanted later in the observation period. HR = hazard ratio. Mintu P. Turakhia et al. JACEP 2016;2:426-433 American College of Cardiology Foundation